Flow Cytometry, Immunoassay Automation, and Molecular Methods

A flow cytometer measures light scatter and fluorescence from cells or particles as they pass an interrogation point. Each recorded particle is an event. Identifying the recorded cells or particles requires a validated combination of specimen preparation, scatter, fluorescence markers, controls, and gating.

Fluidics, optics, and electronics

Forward scatter often correlates with particle size within a fixed optical system and specimen preparation. Side scatter often correlates with refractive and internal complexity. Neither parameter is an absolute measurement of size or granularity, and scatter alone cannot establish lineage. Fluorochrome-labeled antibodies or probes add measurements tied to selected targets.^{1,21 Bishop ML, et al. Clinical Chemistry. 2023.2 Rifai N, et al. Tietz Textbook of Laboratory Medicine. 2023.}

A conventional cytometer sends emission through filters to separate detectors. Because fluorochrome emission spectra overlap, signal from one label can enter another detector. Compensation estimates that spillover from single-stained controls measured on the same instrument and subtracts it mathematically. A spectral cytometer records a wider emission signature and uses spectral unmixing to estimate each fluorochrome contribution. Both methods require controls matched to the fluorochromes, the instrument configuration, and the specimen's autofluorescence.

Plots, gates, and controls

A histogram shows one parameter against event count. A dot or density plot shows two. A gate is an analysis boundary that selects events for another measurement or calculation. A documented gating strategy commonly considers acquisition stability, debris, singlets, viability when it matters, and population-defining markers. A debris gate on forward scatter against side scatter (forward scatter area, FSC-A, against side scatter area, SSC-A, the pulse areas) removes low-scatter events. A singlet gate compares pulse area with pulse height (FSC-A against FSC-H), because a doublet adds area without a matching rise in height. A viability dye separates cells with compromised membranes. A lineage plot such as CD45 against side scatter separates lymphocytes, monocytes, and granulocytes before subset markers are applied. The order of these gates depends on the assay, specimen, controls, and analysis objective. In any order, an event excluded at one gate is excluded from all downstream analysis.

Common controls and their purposes:

• Instrument performance particles track alignment, detector response, background, and day-to-day stability.
• An unstained specimen shows autofluorescence and baseline signal.
• Single-stained controls support compensation or unmixing.
• Fluorescence-minus-one controls can show spread from the other fluorochromes near a difficult gate.
• Viability reagents identify cells with compromised membranes when viability affects interpretation.
• Assay-specific positive and negative materials challenge staining, processing, and analysis.

An isotype control can investigate selected nonspecific binding questions. It does not reproduce every source of background and cannot set every positive gate. Choose controls that resemble the test specimen and pass through the steps they are meant to assess.

Anticoagulant, transport, storage, lysis, fixation, staining time, and acquisition stability are assay-specific. Fixed hour limits cannot be transferred between panels or specimen types. Follow the validated collection and stability instructions, and record any deviation.

Enumeration and immunophenotyping

A dual-platform absolute count combines a cytometric percentage with an absolute count from a hematology analyzer:

Absolute subset count = absolute parent-population count × subset fraction

If the absolute lymphocyte count is 1,800 cells/µL and 16% of the validated lymphocyte gate meets the CD3/CD4 definition:

Absolute CD3/CD4 count = 1,800 cells/µL × 0.16 = 288 cells/µL

Both instruments contribute error. The analyzer's count has its own imprecision, and the denominator can shift if debris or doublets pass through the lymphocyte gate.

Single-platform methods derive the count in the cytometer using a known bead concentration, a measured sample volume, or another validated counting method. They avoid combining two separately measured patient values. Bead recovery, pipetting, acquisition volume, and event loss still require control. CLSI H42-A2 covers specimen handling, staining, instrument calibration, analysis, and reporting for lymphocyte-subset and CD34 enumeration. The document was reaffirmed in 2017.^{33 Clinical and Laboratory Standards Institute. Enumeration of Immunologically Defined Cell Populations by Flow… 2007.}

No marker is unique to one cell or disease. Intensity, maturation, antigen combinations, specimen type, morphology, genetics, and clinical context determine what a marker means, and no single familiar pattern substitutes for the full validated panel. HIV Testing and Monitoring explains CD4 interpretation, and the Immunology, Hematology, Blood Banking, and other area lessons cover their disease-specific panels and how to interpret them.

An automated immunoassay analyzer can perform specimen aspiration, reagent addition, mixing, incubation, bound-free separation when required, signal generation, detection, calculation, and transmission to the laboratory information system. A batch system groups specimens for one assay. A random-access system schedules different assays for different specimens as orders arrive. Actual throughput depends on incubation times, reagent capacity, maintenance, repeats, dilutions, and instrument scheduling.

Use the analytic sequence to locate a failure:

1. The probe or disposable tip identifies and aspirates the specimen.
2. Reagent identity, lot, volume, storage, and onboard stability are checked.
3. The reaction is mixed and incubated under controlled time and temperature.
4. A heterogeneous assay separates bound from free label and washes the reaction vessel.
5. The detector measures absorbance, fluorescence, chemiluminescence, electrochemiluminescence, or another validated signal.
6. Software applies calibration, flags, dilution rules, and the reportable result.

Clot detection, liquid-level sensing, pressure monitoring, barcodes, disposable tips, and wash cycles reduce specific risks. Each safeguard has a detection limit. Carryover can come from a sample probe, reagent probe, mixer, wash station, reaction vessel, or software sequence. An acceptable global carryover check does not show that carryover is acceptable for every high-to-low analyte pair.

In a sandwich assay, signal commonly increases with captured measurand. In a competitive assay, signal commonly decreases as patient measurand displaces labeled material. The analyzer must apply the calibration model the assay design requires. The failure modes also depend on the design. Automation does not remove antigen excess, endogenous antibodies, biotin exposure, matrix effects, or cross-reactivity. Serologic Procedures and Test Results covers immunoassay formats and interpretation.^{1,21 Bishop ML, et al. Clinical Chemistry. 2023.2 Rifai N, et al. Tietz Textbook of Laboratory Medicine. 2023.}

Before patient reporting, verify specimen and reagent handling, carryover where relevant, calibration, precision, bias, measuring interval, reference intervals or decision limits, units, dilution and reflex rules, flags, critical-result handling, and interface transmission. Train operators on loading, maintenance, error recovery, and result review. Quality Control, Method Evaluation, and Quality Management covers the shared verification and quality framework.

The target form, specimen, collection device, transport, storage, pretreatment, extraction, and input amount all affect a molecular result before amplification begins. DNA, RNA, intact cells, cell-free nucleic acid, and fixed tissue need different processes. CLSI MM13, second edition, provides current guidance for specimen collection, transport, preparation, storage, isolation, and evaluation across molecular methods.^{44 Clinical and Laboratory Standards Institute. Collection, Transport, Preparation, and Storage of Specimens for… 2020.}

Extraction and purification

Every extraction combines disruption or lysis with removal of substances that inhibit or interfere with the downstream method.

Extraction efficiency depends on specimen matrix, target location, target length, input, lysis, and elution volume. A method that recovers abundant genomic DNA can still recover cell-free DNA or RNA poorly. Formalin-fixed paraffin-embedded tissue often yields cross-linked, fragmented nucleic acid, and fixation time, block age, tumor selection, extraction chemistry, and assay target length all affect the usable yield. RNA workflows also control ribonuclease exposure and may need a reverse-transcription step.

Mitochondrial targets can be measured from a total-nucleic-acid extract or after a validated enrichment step. The chosen workflow must control recovery, heteroplasmy detection, and interference from homologous nuclear mitochondrial sequences. The assay determines whether separate mitochondrial isolation is needed.^{4,54 Clinical and Laboratory Standards Institute. Collection, Transport, Preparation, and Storage of Specimens for… 2020.5 Clinical and Laboratory Standards Institute. Human Genetic and Genomic Testing Using Traditional and… 2023.}

Quantity, purity, and integrity

Ultraviolet absorbance at 260 nm estimates total nucleic acid under a defined path length and background correction, and absorbance ratios such as A₂₆₀/A₂₈₀ can reveal gross protein or solvent contamination. Pure DNA gives an A₂₆₀/A₂₈₀ ratio near 1.8, and pure RNA a ratio near 2.0.^{99 Powell EA, et al. Extraction of total nucleic acids from bacterial isolates using… 2016.} An acceptable ratio screens only for gross contamination. Purity, integrity, and assay suitability require other evidence. Buffers or low concentration can distort the ratio.

Fluorometric dyes can be more selective for double-stranded DNA, single-stranded DNA, or RNA and are useful at lower concentrations. Gel or capillary electrophoresis and microfluidic systems show size distribution and degradation. None of these measurements guarantees amplifiability. The downstream assay defines acceptable concentration, integrity, fragment distribution, and inhibitor tolerance.^{1,2,41 Bishop ML, et al. Clinical Chemistry. 2023.2 Rifai N, et al. Tietz Textbook of Laboratory Medicine. 2023.4 Clinical and Laboratory Standards Institute. Collection, Transport, Preparation, and Storage of Specimens for… 2020.}

A nucleic-acid probe recognizes a complementary sequence, and stringency describes how closely a duplex must match to survive the reaction conditions. Temperature, salt concentration, probe length, base composition, formamide, and wash conditions set that requirement. Higher temperature, lower salt concentration, and more formamide raise stringency.^{1010 Gibriel A. Effect of target length on specificity and sensitivity of… 2014.} High stringency favors closely matched duplexes. Low stringency permits more mismatches. Probe design must also address homologous sequences, pseudogenes, repetitive regions, and secondary structure, because a strong signal can still come from an unintended complementary sequence.

Agarose gels separate a broad range of nucleic-acid fragments according to size, with concentration, voltage, buffer, and run time setting useful resolution. Polyacrylamide provides finer resolution for small fragments. Capillary electrophoresis uses a sieving polymer and fluorescent detection for fragment analysis and Sanger sequencing. Fluorescent stains and ultraviolet or visible-light systems have product-specific binding, sensitivity, and hazards. Follow the safety data and validated detection method.

Pulsed-field gel electrophoresis (PFGE) periodically changes field direction to separate very large DNA fragments. Its greatest historical role was bacterial subtyping. All 50 US state public-health laboratories completed the transition from PFGE to whole-genome sequencing (WGS) for PulseNet surveillance and outbreak detection in 2019, and WGS is now the standard approach for that work. PFGE resolves fragment sizes beyond the range of conventional gels and remains in use for selected non-surveillance applications.^{66 Centers for Disease Control and Prevention. PulseNet timeline.}

Polymerase chain reaction (PCR) amplifies a region between two primers. A reaction contains template, forward and reverse primers, deoxynucleotide triphosphates, a thermostable polymerase, magnesium and buffer, and any assay-specific probe or control. Cycling repeats three functions:

1. Denaturation separates double-stranded template.
2. Annealing lets primers bind complementary targets.
3. Extension lets polymerase synthesize from each primer's 3′ end.

Perfect doubling would produce 2^N copies from one starting copy after N cycles. Real reactions lose efficiency through reagent limits, inhibitors, competing products, and changing kinetics. The ideal expression describes exponential amplification and is not a quantitative calibration model.

Real-time PCR can use a double-stranded-DNA-binding dye or a sequence-specific probe. A dye reports any compatible double-stranded product, including primer dimers. A hydrolysis probe adds recognition between the primers and separates reporter from quencher during extension. Other probe designs use hybridization-dependent fluorescence or energy transfer. Assess specificity from the primers, probes, cycling conditions, and analysis together. The dye name does not establish performance.

The quantification cycle, written Cq and also called Ct by some platforms, occurs earlier when more amplifiable target is present. Comparing Cq values across runs or assays requires compatible efficiency, threshold, calibration, and input. MIQE 2.0 updates the information needed to evaluate quantitative real-time PCR experiments, including sample processing, assay specificity, efficiency, controls, data analysis, and reporting.^{77 Bustin SA, et al. MIQE 2.0: revision of the Minimum Information for Publication of… 2025.}

Controls that localize failure

A positive amplification control added after extraction cannot prove extraction worked. A negative-template control cannot reveal contamination introduced before amplification setup. Place each control so that it spans the failure it is meant to detect.

Pre-amplification reagent preparation, specimen processing, amplification, and post-amplification analysis use separated space, dedicated supplies, controlled movement, and cleaning validated for the target and surface. Uracil-N-glycosylase systems can reduce carryover from compatible uracil-containing amplicons. They do not remove native target or amplicons made without that chemistry, and the chemistry is incompatible with nested PCR, whose first-round product must survive to the second round. Ultraviolet exposure and chemical decontamination also have material, shadowing, concentration, contact-time, and safety limits. CLSI MM03 remains an archived, technically valid source for amplification controls, inhibitors, false-positive control, and quality assurance in infectious-disease molecular testing.^{88 Clinical and Laboratory Standards Institute. Molecular Diagnostic Methods for Infectious Diseases. 2015.}

Sanger sequencing

Sanger sequencing extends a primer with ordinary nucleotides and fluorescent chain-terminating dideoxynucleotides. Terminated fragments form a nested size series. Capillary electrophoresis separates them, and detector color produces an electropherogram. Base-call quality can fall near the primer, through long homopolymers, across mixed templates, and later in a read. A heterozygous insertion or deletion can create overlapping sequence downstream.

Sanger sequencing remains useful for limited-content assays, fill-in of poorly covered regions, and confirmation of variants already found by another validated method. Low allele fractions, mixed templates, and some sequence contexts exceed what a population-level trace can resolve. The confirming method must have adequate sensitivity for the allele fraction, variant type, and sequence context.^{55 Clinical and Laboratory Standards Institute. Human Genetic and Genomic Testing Using Traditional and… 2023.}

Targeted incorporation and methylation methods

Pyrosequencing detects the pyrophosphate released as each supplied nucleotide is incorporated, and an enzyme cascade converts that release into light. It supports short targeted reads and quantitative applications such as selected methylation measurements. Nucleotide-dispensing order, background, incomplete extension, and homopolymer length affect the signal.

Bisulfite treatment converts most unmethylated cytosine to uracil, which is read as thymine after amplification. Methylated cytosine (5-methylcytosine) is generally retained as cytosine. Conversion efficiency, DNA degradation, incomplete conversion, and sequence-dependent amplification require controls. The sequence comparison estimates methylation only at loci covered by the validated assay.^{1,21 Bishop ML, et al. Clinical Chemistry. 2023.2 Rifai N, et al. Tietz Textbook of Laboratory Medicine. 2023.}

High-throughput sequencing

A clinical next-generation sequencing workflow follows validated steps from specimen to report:

1. Extract and assess nucleic acid.
2. Create a library with platform adapters and sample identifiers.
3. Enrich selected regions by amplification or hybrid capture when the assay is targeted.
4. Generate sequence reads with the validated platform chemistry.
5. Demultiplex, perform quality filtering, and align reads to a stated reference.
6. Call the supported variant classes and apply validated filters.
7. Annotate, classify, interpret, review, and report within the assay's scope.

Fluorescent reversible-terminator systems image incorporated bases cycle by cycle. Semiconductor systems sense hydrogen ions released during incorporation. Platform chemistry affects error patterns, read structure, and detectable variants. Library fragment length, read depth, uniformity, strand balance, mapping quality, allele fraction, contamination, index errors, and difficult sequence regions all influence performance.

Bioinformatics is part of the measurement procedure. Software versions, reference builds, databases, parameters, and report rules need change control and validation. A high average depth does not compensate for a clinically important exon with no usable reads. A negative report covers only the variant classes inside the validated assay. CLSI MM09, third edition, provides current recommendations for design, development, validation, reporting, and continual quality management of human Sanger and high-throughput sequencing tests.^{55 Clinical and Laboratory Standards Institute. Human Genetic and Genomic Testing Using Traditional and… 2023.}

The Microbiology, Hematology, Immunology, Chemistry, Blood Banking, and other area lessons cover target selection and interpretation. Check the instrument principles and controls described here before you release a result from these platforms.